Bonum Therapeutics is a privately held company focused on a platform of allosterically regulated, conditionally active therapeutics that combine an antibody-binding sensor domain with a therapeutic domain to become active only when the sensor binds its target. The company is initially concentrating on regulated immunocytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology, while seeking collaborators to apply the technology in other disease areas. Bonum is a spinout of Good Therapeutics, and the entire Good Therapeutics team joined the new company. The platform was validated by Roche’s August 2022 acquisition of Good Therapeutics for $250 million upfront plus potential milestone payments. Bonum raised $93 million in a Series A to advance its regulated cytokine programs and broaden applications of the platform. The company is backed by investors including Codon Capital, Roche Venture Fund, Rivervest Venture Partners, 3x5 Partners, Digitalis Ventures, and Vivo Capital.

Total raised

$93M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2022